|
Chelation Oral EDTA - A Food Additive with Many Remarkable Properties
On a previous page
intravenous EDTA chelation therapy was discussed. This issue continues
with a discussion of EDTA's protective and enhancing effects as a food
additive on foods and food supplements, as well as some clinically tested
uses of oral EDTA.
The Food and Drug
Administration has approved the synthetic amino acid, ethylene diamine
tetraacetic acid (EDTA), as a pharmaceutical agent for the treatment of
lead and other heavy metal poisoning or exposure. In older literature, the
FDA also approved intravenous EDTA treatment as "possibly effective in
occlusive vascular disorders ... arrhythmias and atrioventricular
induction defects ... and in the treatment of pathologic conditions to
which calcium tissue deposits or hypercalcemia may contribute other than
those listed above."1 These "possibly effective" indications were removed
from FDA-approved literature in the late 1970's for reasons known only to
the FDA. Fortunately, physicians are not limited solely to FDA-approved
indications and may prescribe approved drugs for whatever "unapproved"
conditions they find them to be effective. Consequently, since EDTA is
approved for the treatment of heavy metal poisoning (especially lead),
many physicians continue to use pharmaceutical EDTA with great benefit in
many diseases and conditions other than their officially approved uses.
There are two medical associations whose physician members are trained in
the administration of EDTA for the treatment and prevention of
atherosclerosis and other chronic degenerative diseases. These
organizations are the American College
for Advancement in Medicine
(800-532-3688) and the Great Lakes Association of Clinical Medicine
(800-286-6013). Members of these organizations and their patients find
that EDTA chelation therapy is highly effective as an alternative or
addition to more traditional / widely accepted approaches such as
angioplasty or bypass surgery.
Beneficial Uses of Oral
EDTA in Cardiovascular Disease
In addition to the controversial but widespread recognition of EDTA's
intravenous benefits, is its less well-known clinical uses when
administered orally. Early clinical studies with EDTA reported loss of fat
in rats, reduction of cholesterol in rabbits, and reduced blood pressure
in humans. Consequently, a study of the effects of oral EDTA on patients
with atherosclerosis and/or hypertension was conducted on 10 patients.
Four of these patients had hypertension, four had angina pectoris, one had
peripheral vascular disease (intermittent claudication), and one was
recovering from a heart attack. All were treated with 1 gm of oral EDTA
daily for 3 months. Seven of the ten patients experienced significant
reductions in their cholesterol levels, and blood pressure was reduced in
all ten. The most marked change occurred in the patient with intermittent
claudication, whose cholesterol dropped from 278 mg per 100 ml to 128!
This patient also reported improved exercise tolerance, and the
researchers found improved pulsations in the extremities. The four
patients with angina pectoris also all reported improvement.2
In another series of 20
patients who suffered from hypercholesterolemia, hypertension, angina or
peripheral vascular disease, one gram of EDTA was administered orally
every day for 3 months. During that short time, elevated cholesterol
levels in nine of the patients dropped to within the normal range. No
adverse results were experienced by any of the patients. Angina attacks
were reduced in frequency and severity in five individuals. One person who
previously had suffered a heart attack and experienced several angina
attacks daily thereafter, obtained complete relief.3
In another study, two
patients with extremely elevated cholesterol were treated with oral EDTA.
One patient took EDTA in progressively increasing doses ranging from 500
mg to 4 gm daily for one year, and the other took 1,000 mg daily for three
years (Fig 1).
Although
the first patient suffered a heart attack after three years of therapy,
she recovered uneventfully, and had reduced angina pains and improved
sense of well-being with continued use of EDTA. The second patient - in
addition to hypercholesterolemia - had a condition known as xanthomatosis
(yellowish papules in the skin, related to elevated blood lipids). She not
only experienced dramatic reductions in her cholesterol levels with oral
EDTA treatment, but her skin lesions completely resolved.4 Other
laboratory studies (including kidney and liver function) remained normal
throughout the study for both patients. This is further confirmation of
the safety of oral EDTA, considering that doses as high as 4 gm daily were
consumed.
Further support of the
anti-atherosclerotic effects of oral EDTA are provided by Italian
researchers who found that two grams of oral EDTA daily were effective in
reducing blood cholesterol.5 Scientists at Wayne State University
quantified reversal in atherosclerotic plaque in rabbits that were treated
with daily subcu-taneous EDTA injections.6
EDTA's Multiple Uses as
a Food Additive
In addition to its remarkable pharmaceutical uses, the FDA has also
approved EDTA as a food additive that is generally recognized as safe
(GRAS). EDTA's array of biochemical properties make it extremely valuable
as a food additive. It has the ability to: (1) bind with many metals; (2)
act synergistically with other antioxidants to stabilize fats and oils;
(3) prevent discoloration of potato products; (4) stabilize vitamins; (5)
prevent discoloration of fish and shellfish; (6) prevent flavor changes in
milk; (7) inhibit the thickening of stored condensed milk; (8) enhance the
foaming properties of reconstituted skim milk; (9) prevent color changes
of scrambled eggs prepared from egg powder; (10) preserve canned legumes;
(11) prevent gushing in beer; (12) promote flavor retention and delay loss
of carbonation in soft drinks; (13) prevent oxidation of meat products;
and (14) prevent discoloration of canned fruits and vegetables.7, 8 In
fact, EDTA's use in foods is so widespread that its presence in bloody
evidence even created questions during the O.J. Simpson trial as to its
source-i.e., from food or from blood previously drawn as evidence - since
EDTA is also used as an anticoagulant in blood used for laboratory
studies.
Absorption of Oral EDTA
In
1954, Dr. Harry Foreman and his colleagues performed a landmark study to
determine how much orally administered EDTA the body absorbs.9 The
scientists found that the body absorbs a maximum of 5 per cent of orally
consumed EDTA (Fig. 2) and that it can take up to three days for the EDTA
to be totally excreted. If someone consumed nutritional supplements that
contained 800 mg of EDTA (used as a stabilizer of the ingredients in the
supplement), then we can assume from Dr. Foreman's research that about 40
mg will be absorbed each day and that 1,200 mg will be absorbed each
month. That equates to almost the same amount of EDTA administered in one
intravenous chelation treatment using the low-dose optimum protocol of
Drs. Born and Geurkink10 that was described in last month's Nutritional
News.
Consequently, those unable
to obtain intravenous chelation therapy due to financial, occupational,
geographical or other restraints, or who wish to undergo a less-intensive
preventive approach may be able to obtain many of the same benefits of
intravenous chelation therapy by consuming food-additive EDTA that is used
as a stabilizer in food supplements. Because of concern that long-term use
of EDTA might result in depletion of certain elements, Drs. Ira Manville
and Robin Moser recommended that a potent vitamin and mineral formula be
administered during treatment with EDTA.11 (This should be taken with
meals and not with the EDTA formula.) Dr. Garry Gordon agrees and also
recommends that because EDTA binds to nutritional as well as to unwanted
metallic elements, it is most effective when taken on an empty stomach.12
(1 hr before or 2-3 hours after a meal.) WD
References:
|
1. |
Calcium disodium edetate
and disodium edetate. Federal Register, Volume 35, No. 8, Tuesday,
January 13, 1970, 585-587. |
|
2. |
Perry, H. Mitchell,
Schroeder, Henry A. Depression of cholesterol levels in human plasma
following ethylenediamine tetracetate and hydralazine. J Chronic
Diseases, 1955, 2: 5, 520-532. |
|
3. |
Schroeder, Henry A. A
practical method for the reduction of plasma cholesterol in man. J
Chronic Diseases, 1956, 4: 461-468. |
|
4. |
Perry, Jr., and Camel, G.,
Some effects of CaNa2EDTA on plasma cholesterol and urinary zinc in
man, in: Metal Binding in Medicine, by Marvin J. Seven and L. Audrey
Johnson (eds), 1960, J.B. Lippincott Company, Philadelphia, 209-215. |
|
5. |
Mariani, B., Bisetti, A.,
and Romeo, V. Blood-cholesterol-lowering action of the sodium salt of
calciumethylenediaminotetraacetic acid. Gazz Intern Med e Chir, 1957.
62: 1812-1823. |
|
6. |
Wartman, A., Lampe, T.L.,
McCann, D.S., and Boyle, A.J. Plaque reversal with MgEDTA in
experimental atherosclerosis: Elastin and collagen metabolism. J
Atherosclerosis Res, 1967, 7: 331-341. |
|
7. |
Aamoth, H.L., and Butt,
F.J. Maintaining food quality with chelating agents. Annals New York
Academy of Sciences, 1960, 526-531. |
|
8. |
Furia, T. EDTA in Foods-A
Technical Review. Food Technology, 1964, 18: 12, 1874-1882. |
|
9. |
Foreman, H., Trujillo, T.
The metabolism of C14 labeled ethylenediaminetetra-acetic acid in
human beings. J Lab Clin Med, 1954, 43: 566-571. |
|
10. |
Born, G.R., and Geurkink,
T.L. Improved peripheral vascular function with low dose intravenous
ethylene diamine tetraacetic acid (EDTA). Townsend Letter for Doctors.
July, 1994, # 132, 722-726. |
|
11. |
Manville, I., and Moser,
R. Recent developments in the care of workers exposed to lead. AMA
Arch Indust Health, 1955, 12: 528-538. |
|
12. |
Gordon, G. Oral Chelation
with EDTA. J Holistic Medicine, 1986, 8: 1 & 2, 79-80. |
|